Figure 2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis

ICANS incidence and symptom duration in patients with various electrolyte derangements stratified by receipt of any repletion of the deficient electrolyte. ICANS incidence (top row, error bars represent 95% confidence interval (CI) in patients with (A) serum hypophosphatemia, (B) serum hypokalemia, (C) serum hypomagnesemia, and (D) serum hypocalcemia, stratified by receipt of any electrolyte products containing the deficient electrolyte, from time of CAR T-cell infusion (day 0) until either ICANS symptom onset or day +14. ICANS symptom duration (represented as mean ± SEM) in patients with (E) hypophosphatemia or (F) hypocalcemia stratified by receipt of any electrolyte products containing the deficient electrolyte, from time of CAR T-cell infusion (day 0) until either ICANS symptom onset or day +14. G, ICANS symptom duration in patients with serum hypocalcemia stratified by no repletion (n = 28), any calcium repletion (n = 21), calcium and phosphorus repletion (n = 19), and calcium repletion containing no phosphorus (n = 2). H, ICANS symptom duration in patients with hypokalemia (H) or hypomagnesemia (I) stratified by receipt of any electrolyte products containing the deficient electrolyte, from time of CAR T-cell infusion (day 0) until either ICANS symptom onset or day +14. *, P < 0.05; **, P < 0.01; Fisher exact test for ICANS incidence, unpaired t test for ICANS symptom duration.